BioSpace News Archive

As of September 30, 2017, cash, cash equivalents and short-term investments were $30.4 million, as compared to $10.5 million as of December 31, 2016.

The FDA today issued a safety communication to warn consumers and health care practitioners about the serious injuries and disfigurement that can result from using injectable silicone or products being falsely marketed as FDA-approved dermal fillers for the purpose of enhancing the size of their buttocks, breasts and other body parts.

This is the latest addition to the Company’s market-leading Edit-R portfolio for CRISPR-Cas9 genome engineering.

New Promega Portal Software allows the new and existing Maxwell RSC and Maxprep instruments to work together to transfer sample tracking information from one device to the next to build a complete nucleic acid preparation workflow.

Debio 1347 is an orally available small molecule selectively targeting FGFR 1, 2, 3 signaling pathways and is currently tested in a phase I study in patients with FGFR genomically activated advanced solid tumors.

The Clolar brand and generic had U.S. sales of approximately $53 million MAT for the most recent twelve months ended in September 2017, according to IMS Health.

Dr. Sanjiv Shah from Northwestern Memorial Hospital’s Center for Heart Failure at the Bluhm Cardiovascular Institute in Chicago will be presenting on behalf of the investigators, at the Innovative Therapies and Novel Applications session of the Late-Breaking Science program.

It takes less than one-tenth of a second - a fraction of the time previously thought - for the sense of smell to distinguish between one odor and another, new experiments in mice show.

On Nov. 6, 2017, Merck commenced the Offers in accordance with the terms and conditions set forth in the Offer to Purchase, dated Nov. 6, 2017.

ITUS has formed a subsidiary, Certainty Therapeutics, to develop and commercialize the innovative CAR-T technology.